Dr.Reddy's Laboratories Announcedthe Launch of Generic Version of Nexavar(Sorafenib) Tablets, USP, 200 Mg in the United States

On June 14, 2022,- Dr. Reddy’s Laboratories Ltd, along with its subsidiaries together referred to as “Dr. Reddy’s” broadcasted the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic correspondent of Nexavar (sorafenib) Tablets in the United States market after the approval by the U.S. Food and Drug Administration (USFDA).

Dr.Reddy's Laboratories Announcedthe Launch of Generic Version of Nexavar(Sorafenib) Tablets, USP, 200 Mg in the United States

On June 14, 2022,- Dr. Reddy’s Laboratories Ltd, along with its subsidiaries together referred to as “Dr. Reddy’s” broadcasted the launch of Dr. Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic correspondent of Nexavar (sorafenib) Tablets in the United States market after the approval by the U.S. Food and Drug Administration (USFDA).

The Chief Executive Officer, North America Generics of Dr. Reddy’s Laboratories Inc., Marc Kikuchi, expressed his pleasure to launch this significant generic product, exemplifying. Reddy’s continued commitment to bringing out reasonable price generic medicines to the market for patients. Dr. Reddy’s Sorafenib Tablets, USP, are obtainable in 200 mg tablets in the bottle count sizes of 120.

Dr. Reddy’s Laboratories Ltd. is a unified pharmaceutical company, dedicated to providing innovative and affordable medicines for improved well-being and healthier lives. Dr. Reddy offers an assortment of products and services comprising APIs, generics, biosimilars, custom pharmaceutical services, and distinguished formulations. Their major therapeutic areas of attention include gastrointestinal, diabetology, oncology, cardiovascular, pain management as well as dermatology. Dr. Reddy operates in markets throughout the world. Their major markets include – USA, Russia & CIS countries, India, and Europe.